Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 26, 2024
Deals
Sarepta broadens pipeline via siRNA deal with Arrowhead, paying $825M up front
CEO Ingram sees “the one significant strategic transaction” to transform Sarepta’s future, while Arrowhead preps for first-ever launch
BioCentury | May 10, 2024
Product Development
Epigenetic editors at ASGCT: animal models address the durability question
As the new modality advances, the promise of durability is bearing out in preclinical models
BioCentury | Feb 21, 2024
Product Development
Rare disease spotlight: treating a facial muscular dystrophy at its root
As the most advanced FSHD programs aim to reduce muscle cell death, the next wave is targeting the disease’s genetic cause
BioCentury | Jun 8, 2023
Emerging Company Profile
KateTx: sending more AAV to muscle, less to liver
Kate’s platform for increasing the potency and decreasing the liver tox of AAVs has attracted Astellas as a partner
BioCentury | Jun 2, 2023
Product Development
Epigenome editing companies showcase progress at ASGCT
Modalis accomplishes gene activation, while Tune achieves gene repression, both in non-human primates
BioCentury | Oct 4, 2022
Deals
Muscular dystrophy deal with Sanofi strengthens miRecule ahead of series A
NIH spinout hands off rights to RNA therapy as head and neck cancer program moves toward clinic
BioCentury | Aug 18, 2022
Product Development
Rise of the dead Cas to edit the epigenome
Start-ups are tuning gene expression by hitching a range of effector domains to catalytically dead CRISPR machinery
BioCentury | Jul 13, 2022
Emerging Company Profile
Epic Bio: Epigenome editing via compact components
Horizons Ventures leads $55M series A for start-up developing compact epigenome editors with all-in-one AAV delivery
BioCentury | Jan 1, 2021
Targets & Mechanisms
A snapshot of target innovation in 2020
An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
Items per page:
1 - 10 of 18